Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial

In the gefurulimab group, the most common TEAEs were injection site reactions (9.9%), headache (9.9%), and back pain (7.6%). Twelve people treated …
Source: back pain